ASA 75-200 mg daily + clopidogrel 75 mg daily + warfarin (lowest recommended target INR)

for 6 weeks versus 6 months

Composite of death, MI, definite stent thrombosis, stroke, or major bleeding at 9 months

6 weeks triple therapy: 9.8% (30 events)

6 months triple therapy: 8.8% (27 events) (p=0.63)

• The trial was underpowered for its primary endpoint
• No differences in efficacy or safety were found
• Prevalence of AF: 84%
• Use of PPI: 37.2%